THE Therapeutic Goods
Administration has announced the
recall of a batch of Chlorofluor Gel
due to bacterial contamination.
The product is being recalled by
Professional Dentist Supplies, after
testing of unopened bottles from
batch BK 119 detected high levels
of Burkholderia cepacia.
The affected batch has been
associated with two cases of B.
cepacia infection at the Royal
Adelaide Hospital, where the batch
has already been removed.
Chlorofluor Gel is an oral
hygiene product containing 2mg/
ml of chlorhexidine, and can be
purchased over the counter.
According to the TGA B. cepacia
poses little medical risk to
healthy people, but could prove
problematic for people with
weakened immune systems.
Effects vary widely and range
from no symptoms at all through
to serious respiratory infections,
especially in patients with chronic
lung diseases such as cystic fibrosis.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.